HI
KLRS

Harbour Investments’s Kalaris Therapeutics KLRS Stock Holding History

Harbour Investments’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75 Buy
+13
New +$115 ﹤0.01% 4540
2021
Q4 		– Sell
-1
Closed – – 3778
2021
Q3 		$0 Buy
+1
New +$463 ﹤0.01% 4049

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Harbour Investments's KLRS Position: Q1 2026 in Review

Harbour Investments opened a new position in Kalaris Therapeutics (KLRS) in Q1 2026: 13 shares worth $75. The stake represents ﹤0.01% of the portfolio and ranks #4540 among its holdings. This is a return to the name: Harbour Investments previously reported a position in KLRS as recently as Q3 2021.

Harbour Investments first reported a position in KLRS in Q3 2021 and has held it in 2 quarters since. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Harbour Investments held 13 shares of Kalaris Therapeutics worth $75 as of Q1 2026.
  • Kalaris Therapeutics was a new Harbour Investments position in Q1 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #4540 holding.
  • Harbour Investments first reported a position in Kalaris Therapeutics in Q3 2021 and has held it in 2 quarters since.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.